智飛生物(300122.SZ):重組結核桿菌融合蛋白(EC)獲得藥品註冊批件
格隆匯4月29日丨智飛生物(300122.SZ)公佈,2020年4月28日,公司收到全資子公司智飛龍科馬的報告,子公司收到國家藥品監督管理局下發的重組結核桿菌融合蛋白(EC)藥品註冊批件。EC適用於結核桿菌感染診斷,皮試結果不受卡介苗(BCG)接種的影響,也可用於輔助結核病的臨牀診斷。
該產品的上市,解決了已應用百年之久的結核菌素類產品(PPD等)無法鑑別卡介苗接種與結核感染的難題,作為體內診斷製品用於結核桿菌感染診斷和結核病的臨牀輔助診斷,市場應用前景廣闊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.